

PATENT Attorney Docket No. 056291-5296

TITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)		
David Michael ANDREWS, et al.) Confirmation No.: 3394		
Application No.: 10/586,954) Group Art Unit: 1614		
Filed: July 25, 2006	Examiner: Unassigned		
For: IMIDAZOLO-5-YL-2-ANILINOPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION) Date: April 20, 2007)		

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Window, Mail Stop Amendment
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants request the Examiner to consider this Supplemental Information Disclosure Statement and the documents listed on the attached Form PTO-1449. To the best of the undersigned's knowledge, this Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application. Accordingly, Applicants do not believe a fee is due for filing this Supplemental Information Disclosure Statement.

With the exception of U.S. Patents and Publications, copies of the listed documents are attached. Applicants respectfully request that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.

ATTORNEY DOCKET NO.: 056291-5296

Application No.: 10/586,954

Page 2

This submission does not represent that a search has been made or that no better art exists and

does not constitute an admission that each or all of the listed documents are material or constitute

"prior art." Applicants reserve the right to take appropriate action to establish the patentability of the

disclosed invention over the listed documents, should one or more of the documents be applied against

the claims of the present application.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized

by this paper to charge any additional fees during the entire pendency of this application including fees

due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time

fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a

CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R. §

1.136(a)(3).

Respectfully Submitted,

Morgan Lewis & Bocking

Date:

April 20, 2007

Morgan Lewis & Bockius LLP

Customer No. 09629

1111 Pennsylvania Avenue, N.W.

Washington, D.C. 20004

Tel. No.: 202-739-3000

By:

Donald J. Bird

Registration No. 25,323

Tel. No.: (202) 739-5915

Fax No.: (202) 739-3001

Attorney Docket No. Application No.: INFORMATION DISCLOSURE CITATION 056291-5296-US 10/586,954 several sheets if necessary) Applicants: ANDREWS et al. APR 2 0 2007 PTO Form 1449 Filing Date: July 25, 2006 Group Art Unit: 1614 April 20, 2007 U.S. PATENT DOCUMENTS Initial Document No. Date Name Class Sub-Class Filing Date US 4,983,608 January 8, 1991 Effland et al. A₁ May 14, 1996 A2 US 5,516,775 Zimmerman et al. A3 US 5,521,184 May 28, 1996 Zimmermann A4 US 5,610,303 March 11, 1997 Kimura et al. **A5** US 5,739,143 April 14, 1998 Adams et al. US 5,859,041 January 12, 1999 **A6** Liverton et al. **A**7 US 6,835,726 December 28, 2004 Cushing et al. **A8** US 20030144303 July 31, 2003 Hawley et al. Α9 US 20060079543 April 13, 2006 Sum et al. A10 US 20030191307 October 9, 2003 Blumenkopf et al. FOREIGN PATENT DOCUMENTS Document No. Date **Country** Class Sub-Class Translation **B**1 CA 2231765 September 13, 1998 Canada B2 EP 0135472 January 18, 1989 **EPO** US 4,659,363 **B3** EP 0363002 June 22, 1994 **EPO B4** EP 0379806 April 10, 1996 EPO **B**5 EP 0945443 August 13, 2003 **EPO** July 23, 2003 **B6** EP 1056742 **EPO B**7 HU 220630 Hungary March 28, 2002 Claims **B8** WO 91/18887 December 12, 1991 WIPO **B9** WO 92/20642 November 26, 1992 WIPO B10 WO 95/09847 April 13, 1995 WIPO B11 WO 95/09851 April 13, 1995 WIPO B12 WO 95/09852 April 13, 1995 WIPO B13 WO 95/09853 April 13, 1995 WIPO WO 95/15952 **B14** June 15, 1995 **WIPO** B15 WO 96/05177 February 22, 1996 WIPO B16 WO 96/28427 September 19, 1996 **WIPO B17** WO 96/40143 December 19, 1996 **WIPO** WO 97/19065 **B18** May 29, 1997 WIPO B19 WO 97/35856 October 2, 1997 WIPO **B20** WO 97/40017 October 30, 1997 WIPO B21 WO 97/44326 November 27, 1997 WIPO B22 WO 9747618 December 18, 1997 **WIPO B23** WO 98/11095 March 19, 1998 WIPO B24 WO 98/16230 April 23, 1998 **WIPO B25** WO 98/18782 May 7, 1998 **WIPO** B26 WO 98/25619 June 18, 1998 WIPO **B27** WO 98/33798 August 6, 1998 WIPO OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) Examiner Date Considered Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Attorney Docket No. Application No.: INFORMATION DISCLOSURE OF TAXION 056291-5296-US 10/586,954 (Use several sheets if necessary) Applicants: ANDREWS et al. APR 2 0 2007 PTO Form 1449 Filing Date: July 25, 2006 Group Art Unit: 1614 April 20, 2007 **U.S. PATENT DOCUMENTS** Initial Document No. Class Sub-Class Filing Date FOREIGN PATENT DOCUMENTS Document No. Date Country Class Sub-Class Translation WO 98/41512 B28 September 24, 1998 WIPO B29 WO 98/54093 WIPO December 3, 1998 **B30** WO 98/56788 December 17, 1998 **WIPO** B31 WO 99/01136 Jan 14, 1999 **WIPO B32** WO 99/18096 April 22, 1999 WIPO B33 WO 99/18942 April 22, 1999 WIPO **B34** WO 99/31073 June 24, 1999 WIPO US 6,432,963 **B35** WO 99/32121 July 1, 1999 WIPO **B**36 WO 99/41253 August 19, 1999 **WIPO B37** WO 99/50250 October 7, 1999 **WIPO B38** WO 99/50251 October 7, 1999 **WIPO B39** WO 00/12485 March 9, 2000 **WIPO B40** WO 00/12486 March 9, 2000 **WIPO** March 30, 2000 B41 WO 00/17202 **WIPO** B42 WO 00/17203 March 30, 2000 **WIPO** B43 WO 00/21926 April 20, 2000 WIPO **B44** WO 00/25780 May 11, 2000 WIPO B45 WO 00/26209 May 11, 2000 WIPO B46 WO 00/39101 July 6, 2000 WIPO **B47** WO 00/44750 August 3, 2000 **WIPO** B48 WO 00/49018 August 24, 2000 **WIPO** B49 WO 00/53595 September 14, 2000 WIPO B50 WO 00/55161 September 21, 2000 **WIPO** B51 WO 00/59892 October 12, 2000 **WIPO** December 28, 2000 B52 WO 00/78731 WIPO **B53** WO 01/14375 March 1, 2001 WIPO B54 WO 01/29009 April 26, 2001 WIPO B55 WO 01/30778 May 3, 2001 WIPO WO 01/37835 **B56** May 31, 2001 **WIPO** B57 WO 01/47897 July 5, 2001 WIPO B58 WO 01/47921 July 5, 2001 **WIPO** B59 WO 01/60816 August 23, 2001 **WIPO B60** WO 01/64653 September 7, 2001 **WIPO** B61 WO 01/64654 September 7, 2001 **WIPO** OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) Examiner Date Considered Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

PTO Form 1445

April 20, 2007

APR 2 0 2007

Attorney Docket No. 056291-5296-US

Application No.: 10/586,954

Applicants: ANDREWS et al.

Filing Date: July 25, 2006

Group Art Unit: 1614

Abstract

U.S. PATENT DOCUMENTS								
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date	
			FOREIGN PAT	TENT DOCUMENTS				
		Document No.	Date	Country	Class	Sub-Class	Translation	
	B62	WO 01/64655	September 7, 2001	WIPO				
	B63	WO 01/64656	September 7, 2001	WIPO				
	B64	WO 01/72717	October 4, 2001	WIPO				_
	B65	WO 02/04429	January 17, 2002	WIPO				_
	B66	WO 02/65979	August 29, 2002	WIPO				_
	B67	WO 02/66481	August 29, 2002	WIPO		1		_

November 21, 2002 **B68** WO 02/92573 WIPO B69 WO 02/96887 December 5, 2002 **WIPO** B70 WO 02/96888 December 5, 2002 **WIPO** US 20040224966 B71 WO 03/007955 January 30, 2003 WIPO **B72** WO 03/029249 April 10, 2003 WIPO **B73** WO 03/031446 April 17, 2003 **WIPO**

B74 WO 03/076433 September 18, 2003 WIPO B75 WO 03/076434 September 18, 2003 **WIPO B76** WO 03/076435 September 18, 2003 WIPO WO 03/076436 September 18, 2003 B77 **WIPO B78** WO 04/005283 January 15, 2004 **WIPO**

> May 27, 2004 **WIPO** May 27, 2004 **WIPO** October 14, 2004 **WIPO**

October 14, 2004 WIPO November 25, 2004 WIPO November 25, 2004 WIPO

WO 05/012298 February 10, 2005 **WIPO** WO 05/037800 April 28, 2005 **WIPO** WO 05/075468 August 18, 2005 **WIPO**

September 14, 2006

WO 05/113550 December 1, 2005 **WIPO** WO 05/116025 December 8, 2005 WIPO WO 06/034872 April 6, 2006 **WIPO**

B91 WO 06/050076 May 11, 2006 WIPO B92 WO 06/064251 June 22, 2006 WIPO **B93** WO 06/075152 July 20, 2006 **WIPO**

Examiner

WO 06/095159

WO 04/043467

WO 04/043953

WO 04/087698

WO 04/087699

WO 04/101549

WO 04/101564

B79

B80

B81

B82

B83

B84

B85

B86

B87

B88

B89

B90

B94

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date Considered

WIPO

INFORMATION DISCLOSURE CITATION			Attorney Docket No. 056291-5296-US		Application No.: 10/586,954			
	J)	Use several sheets if nece	ADD 0 0 2007	Aŗ	pplicants: ANDREWS et	al.		
		PTO Form 1440, April 20, 2007			Filing Date: July 25, 20)06	Group	Art Unit: 1614
			U.S. PAT	TEN	NT DOCUMENTS	-	-	
Initial		Document No.	Date		Name	Class	Sub-Class	Filing Date
						<u></u>		
				PAT	TENT DOCUMENTS			
	4-	Document No.	Date	-	Country	Class	Sub-Class	Translation
			·			<u></u>		
		OTHER DO	OCUMENTS (Includ	ling_/	Author, Title, Date, Pert	tinent Pa	ges. etc.)	
	C1	Blain, S. et al. "Differe cyclin D2-Cdk4" The J	ential interaction of the Journal of Biological (ne cycl Chem	clin-dependent kinase (Cd mistry, 1997, Vol 272, No.	dk) inhibito 0.41, pp 25	tor p27 ^{Kip1} with 5863-25872.	
	1	Boschelli, D. et al. "Syr	nthesis and tyrosine ki	kinase	e inhibitory activity of a se	series of 2-	-amino-8H-pyr	rido[2,3-
	C2	d]pyrimidines: identific Med. Chem., 1998, Vol	cation of potent, select	tive r	platelet-derived growth fa	actor recep	ptor tyrosine k	inase inhibitors" J.
	C3	Dandy I at al "Danatic	ions of some quinazoli	ine cr	compounds with ethoxyme	ethylenem	alonic acid de	rivatives" J.
	C4	El Kardayay M at al "	"2,4-Bis(substituted)-5	5-nitr	ropyrimidines of expected	d diuretic	action" Egypt	. J. Chem., 1986, 29
	C5	Fiziol Akt Veshchestva	a, 1975, 7, pp 68-72.					
	C6	Ghosh, D. et al. "2,4-Bi 974-975.	is(arylamino)-5-methy		rimidines as antimicrobial			
	1	Ghosh, D., "2,4-Bis(ary	ylamino)-6-methyl py	rimid	dines as antimicrobial ager	nts" Cher	nical Abstract	s, 1981, Vol 95,
		No.11, Columbus, Ohio 58, No.5, pp 512-513, I	o, US; Abstract No. 97 India.	7712f	ef; pp 648; XP002109184 a	abstract &	& J. Indian Che	em. Soc., 1981, Vol
		1987, Vol 24, pp 1305-1	-1307.		ubstituted 4-amino-5-pyrin			•
	C9	Simone, J. "Oncology: i	introduction" Bennett,	<u>ι, J. Τ</u>	Textbook of Medicine, 20t	th Edition	, Vol 1, 1996,	pp 1004-1010.
	C10	Volin, M. et al. "Cell cy d594-601.	ycle implications in the	ne patl	thogenesis of rheumatoid a	arthritis"]	Frontiers in Bi	ioscience, 2000, 5,
	C11	Zimmermann, J. et al. selective inhibitors of pr	Phenylamino-pyrimic rotein kinase C (PKC)	ine ())" Ar	(PAP) derivatives: a new c rch. Pharm. Pharm. Med. (class of po Chem. 19	otent and 196, 329 (7), p	p 371-376.
		 						
	 							
		1						
	11	t 						
	\vdash							

		<i></i>						
caminer			Date Con	asider	red	_		